Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: March Update

Performance overview

Value at beginning of month: $148,917.34

Value at end of month: $152,872.55

Month over month change: +2.66%

Total IRR: 21.16%

Related indices, monthly change

NASDAQ: +1.76%

IVV (iShares Core S&P 500): +1.15%

IBB (iShares NASDAQ Biotechnology Index): -2.88%

MXI (iShares Global Materials): +1.33%

VEGI (iShares MSCI Global Agriculture Producers): -0.82%

ICLN (iShares Clean Energy): +1.03%

Individual performances


There were several companies that grew by double digit percentages this month, but the real surprising company was Amyris. Due to another disappointing year of earnings, investors may be getting suspicious that Amyris may ever be able to reach productivity. Their stock price fell over 50% after their earnings release, and now sits at its lowest price ever.

Changes made to index

Added Precision Biosciences after their IPO.

You can view the index here.

Allocation as of March 29, 2019


Calvin Schmidt Synthetic Biology Index: April Update

Calvin Schmidt Synthetic Biology Index: February Update